OXB — Oxford BioMedica Cashflow Statement
0.000.00%
- £312.12m
- £323.69m
- £89.54m
Annual cashflow statement for Oxford BioMedica, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -14.5 | -5.69 | 19.9 | -46 | -189 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 4.13 | 4.12 | 5.03 | 1.53 | 106 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.04 | -5.15 | -11.9 | 5.47 | 25 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -3.51 | 3.12 | 25.5 | -12.6 | -28.5 |
Capital Expenditures | -25.8 | -13.4 | -9.46 | -16.3 | -9.83 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 6.38 | 2.56 | 0 | -40.2 | 12.6 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -19.4 | -10.8 | -9.46 | -56.5 | 2.81 |
Financing Cash Flow Items | -4.15 | -1.72 | -0.873 | -13.9 | -10.2 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 6.91 | 38.2 | 46.2 | 98.6 | -12.7 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -16 | 30.5 | 62.2 | 32.3 | -37.6 |